Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Activity of Zelasudil (RXC007) in Idiopathic Pulmonary Fibrosis
NCT05570058Phase 2Active, not recruiting
- Sponsor
- Redx Pharma
- Start
- Sep 2022
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 2, randomised, double-blind trial of zelasudil in idiopathic pulmonary fibrosis (IPF) (3 cohorts), sponsored by Redx Pharma. Primary endpoints: Incidence and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs) at 12 weeks and Changes in safety laboratory parameters, vital signs, and ECGs at 12 weeks. Started Sep 2022; status: active, not recruiting.
02
Drugs
zelasudil
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT05570058.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05570058.